A Phase 1/2 interventional study of CYH33 and Placebo in PIK3CA-Related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM), sponsored by Haihe Biopharma Co., Ltd.. Recruiting at 15 sites in 2 countries. Per ClinicalTrials.gov, last updated 2026-06-29.
Sponsored by Haihe Biopharma Co., Ltd. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Vascular Malformations with a site in China — 2 open to participants now, 3 under way, none of them phase 3. Vascular Malformations · China.
Among the 10 studies in Vascular Malformations with a site in China, this one is the 4th largest by planned enrollment, is the only one that started in 2023, is one of 2 in phase 1/2, and was the 8th registered.
80 studies on the registry are indexed under Vascular Malformations; 34 are open to participants now.
Browse Vascular Malformations studies →2 of the 10 studies in Vascular Malformations with a site in China are open now. Recruiting first, the newest first:
Xuanwu Hospital, Beijing · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 22 Vascular Malformations studies recruiting now, 13 (59%) set no upper age limit and 7 (32%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 3
First in 2010; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 141 is above the median of 53 across 50 interventional studies indexed under Vascular Malformations.
Median enrollment 78 across the 10 interventional studies. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 10 have an industry lead sponsor. The 7 most frequent:
Haihe Biopharma Co., Ltd. is the lead sponsor of 20 studies on the registry; 4 are open to participants now.
Haihe Biopharma Co., Ltd. has 1 study filed under Vascular Malformations — fewer than ten, so there is no comparison to draw.
1 of the studies in Vascular Malformations with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07072403West China HospitalTrametinib Treatment for Complicated Vascular Anomalies | 2027-07-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Vascular Malformations with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a multi-center, open-label, single arm, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CYH33 in patients with PIK3CA-related overgrowth spectrum (PROS) and PIK3CA-related vascular malformations (PRVM)
Key inclusion criteria:
Key exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase I Adult Cohort: Adult patients with PIK3CA-related overgrowth spectrum (PROS) or PIK3CA-related vascular malformations (PRVM) will receive escalating oral doses of CYH33 to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D). Expansion cohorts may be opened to further assess safety, tolerability, pharmacokinetics, and preliminary efficacy.
Drug: CYH33
Phase I Adolescent Cohort: Adolescent patients with PIK3CA-related overgrowth spectrum (PROS) or PIK3CA-related vascular malformations (PRVM) will receive escalating oral doses of CYH33 to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D). Expansion cohorts may be opened to further assess safety, tolerability, pharmacokinetics, and preliminary efficacy.
Drug: CYH33
Phase II PROS Cohort: An open-label, single-arm cohort. Adult and adolescent patients with PROS will receive CYH33 at RP2D. Dose escalation may be allowed based on tolerability and clinical assessment. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal.
Drug: CYH33
Phase II PRVM Cohort: Adult and adolescent patients with PRVM will be randomized 2:1 to CYH33 or placebo during double-blind period. After 8 weeks of treatment, all patients will enter an open-label extension phase to receive CYH33. Treatment continues until disease progression, unacceptable toxicity, or withdrawal.
Drug: CYH33 · Drug: Placebo
CYH33: Participants will receive oral CYH33 once daily. The starting dose for adults in Phase I is 10 mg QD; adolescents begin at 5 mg QD. In Phase II, patients will receive RP2D determined in the Phase I study.
Placebo: Matching placebo tablets will be administered once daily during the double-blind period of the Phase II PRVM cohort. Patients randomized to placebo will switch to CYH33 at the end of the blinded phase.
Phase I: The maximum tolerated dose (MTD) and/or phase II recommended dose (RP2D)
To evaluate the safety and tolerability of CYH33 and determine the maximum tolerated dose (MTD) and/or phase II recommended dose (RP2D) of CYH33 in adult and adolescent patients
Time frame: 27 weeks
Phase II PROS Cohort: BIRC-assessed objective response rate (ORR) at Week 24
Proportion of patients achieving ≥20% reduction from baseline in the sum of target lesion volumes, with no progression of non-target lesions and no new lesions, as assessed by blinded independent review committee (BIRC).
Time frame: Baseline to 24weeks
Phase II PRVM Cohort: BIRC-assessed objective response rate (ORR) at Week 24
Proportion of patients achieving ≥20% reduction from baseline in the sum of target lesion volumes, with no progression of non-target lesions and no new lesions, as assessed by blinded independent review committee (BIRC).
Time frame: Baseline to 24weeks
Phase I: Pharmacokinetics of CYH33 and its metabolite I27 in the study population: Area Under the Curve from 0 to 24 hours (AUC0-24h)
AUC0-24h of CYH33 and its metabolite I27 following drug administration will be assessed.
Time frame: Pre-dose and at 1, 2, 4, 6, 8, and 24 hours post-dose on Day 1 and Day 29.
Phase I: Pharmacokinetics of CYH33 and its metabolite I27 in the study population: Maximum Concentration (Cmax)
Cmax of CYH33 and its metabolite I27 following drug administration will be assessed.
Time frame: Pre-dose and at 1, 2, 4, 6, 8, and 24 hours post-dose on Day 1 and Day 29.
Phase I: Pharmacokinetics of CYH33 and its metabolite I27 in the study population: Minimum Concentration (Cmin)
Cmin of CYH33 and its metabolite I27 following drug administration will be assessed.
Time frame: Pre-dose on Day 29.
Phase I: Pharmacokinetics of CYH33 and its metabolites in the study population: Time to Maximum Concentration (Tmax)
Tmax of CYH33 and its metabolite I27 following drug administration will be assessed.
Time frame: Pre-dose and at 1, 2, 4, 6, 8, and 24 hours post-dose on Day 1 and Day 29.
Phase I: Pharmacokinetics of CYH33 in the study population: Steady-State Apparent Clearance (CLss/F)
CLss/F of CYH33 following drug administration will be assessed.
Time frame: Pre-dose and at 1, 2, 4, 6, 8, and 24 hours post-dose on Day 1 and Day 29.
Phase I: The response rate and target lesion volume reduction rate as assessed by the investigators at each dose level
A responder is defined as a ≥ 20% reduction in target lesion volume from baseline and in absence of progression of non-target lesions and without new lesions. The proportion of patients with reduced target lesion volume compared to baseline will also be assessed.
Time frame: week 27
Phase I: The changes from baseline in the Brief Pain Inventory (BPI) Worst Pain Intensity Numerical Rating score at each dose level, based on the patient-reported outcome (PRO) diary
Pain is categorized into 11 levels from 0 to 10, where 0 indicates no pain at all and 10 indicates the most severe pain imaginable. Patients should assess and record their pain levels over the past 24 hours in the patient diary at each scheduled assessment visit.
Time frame: Up to approximately 48 months
Phase I: The changes from baseline in the Patient Global Impression of Change scale at each dose level, based on the patient-reported outcome (PRO) diary
Patients will compare their global impression of symptom changes with the pretreatment status, then categorize them into the following 7 grades: significantly relieved, moderately relieved, minimally relieved, no change, minimally worse, moderately worse, or significantly worse at each scheduled assessment visit.
Time frame: Up to approximately 48 months
Phase I: The changes from baseline in the quality of life scores at each dose level, based on the patient-reported outcome (PRO) diary
The Quality of Life Scale (EQ-5D-5L) consists of two parts. Part 1 assesses five quality-of-life-related indicators, with each indicator graded into five distinct levels for self-evaluation by the patient. Part 2 consists of patients' self-assessment of health status, with a maximum score of 100 points and a minimum score of 0 points.
Time frame: Up to approximately 48 months
Phase I: Frequency and severity of adverse events
The type, incidence, and severity of adverse events (AEs) (assessed according to the CTCAE Version 5.0 criteria).
Time frame: Up to approximately 48 months
Phase II : BIRC-assessed ORR at Week 48 (PROS cohort and PRVM cohort)
BIRC-assessed ORR at Week 48 (PROS cohort and PRVM cohort) Time Frame: From start of CYH33 treatment to Week 48
Time frame: Week 48
Phase II: BIRC-assessed ORR at Week 8 (Double-blind Period in PRVM cohort)
BIRC-assessed ORR at Week 8 (Double-blind Period in PRVM cohort) Time Frame: From randomization to Week 8
Time frame: Week27
Phase II: BIRC-assessed ORR at Weeks 8 and 16 (PROS cohort and PRVM cohort)
BIRC-assessed ORR at Weeks 8 and 16 (PROS cohort and PRVM cohort) Time Frame: From start of CYH33 treatment to Weeks 8 and 16
Time frame: Weeks 8 and Week 16
Phase II : Change from Baseline in Target Lesion Volume (PROS cohort and PRVM cohort)
Change from Baseline in Target Lesion Volume (PROS cohort and PRVM cohort) Time Frame: From start of CYH33 treatment to Week 48
Time frame: Up to approximately 48 months
Phase II: Investigator-assessed overall clinical response (PROS cohort and PRVM cohort)
Investigator-assessed overall clinical response (PROS cohort and PRVM cohort) Time Frame: From start of CYH33 treatment to Week 48
Time frame: Up to approximately 48 months
Phase II: Change from Baseline in Patient-Reported Outcomes (PROS cohort and PRVM cohort)
Change from Baseline in Patient-Reported Outcomes (PROS cohort and PRVM cohort) Time Frame: Up to approximately 48 months
Time frame: Up to approximately 48 months
Phase II: Safety and Tolerability of CYH33 (PROS cohort and PRVM cohort)
Safety and Tolerability of CYH33 (PROS cohort and PRVM cohort) Time Frame: Up to approximately 48 months
Time frame: Up to approximately 48 months
Phase II :Plasma Drug Concentrations of CYH33 and Metabolite I27
Plasma Drug Concentrations of CYH33 and Metabolite I27
Time frame: Up to 5 cycles (approximately 20 weeks)
Started Aug 2023 (actual). Primary completion is estimated for Dec 2029, 76 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CYH33